Noramco Adds Capacity and Dual Sources of Supply for Cannabinoids

Noramco, a leader in controlled substances and cannabinoids, is adding commercial-scale capacity of dronabinol (THC) at its Athens, Georgia, United States facility. The expansion comes in response to rising demand for its highly pure cannabidiol (CBD) and dronabinol (THC) analogs of cannabis sativa.

Following implementation, Noramco will supply both THC and CBD from facilities in the United States and Europe.

“Today’s announcement is further evidence that our pharmaceutical and healthcare customers place a significant value on our high-purity products and a fully redundant supply chain for cannabidiol and dronabinol,” said Bill Grubb, Vice President of Business Development and Innovation, Noramco.

Clinical samples will be available from the Athens site in 2018, with commercial production commencing in the first quarter of 2019. Both dronabinol in oil and dronabinol in ethanol are available in Athens. Previously, the company produced these products only in Europe.

“Providing a manufacturing process that is identical in both Europe and the United States, we now offer pharmaceutical customers the option to source our highly pure product from one or both facilities. The Athens site, which already supplies other high-potency parenteral actives commercially, is a world-class cGMP facility ideally suited for products like dronabinol in oil, or ethanol,” Grubb added.

Noramco is a leader in analogs of cannabis sativa designated for use in regulated pharmaceutical and healthcare markets, offering 32 cannabinoid ingredients, degradants, metabolites, or analytical reference standards. The company has more than a decade of expertise in pharmaceutical-grade cannabinoids, with major milestones in highly pure production processes beginning in 2007.

Noramco Partnerships Highlight the Breadth of Therapies and Importance of Purity

Within the last 12 months, Noramco has entered into a series of supply contracts with pharmaceutical and healthcare companies around the world that require highly pure cannabinoids in order to advance therapies through the regulatory approval process, and move to commercial production. These include companies working on therapies with indications such as anti-emetic, sleep disorder, heart wellness, and others.

“Noramco’s decade of experience in cannabinoids, proven highly pure synthesis process, and focus on the needs of cannabinoid-based pharmaceutical developers is helping to expand the potential of cannabinoid-based therapies,” Grubb said.